doxazosin and celecoxib

doxazosin has been researched along with celecoxib in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Bender, A; Czobor, P; Jelinek, B; Málnási-Csizmadia, A; Peragovics, Á; Simon, Z; Tombor, L; Végner, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Abo-Talib, NF; Bebawy, LI; Moustafa, AA1
Jhang, JF; Jiang, YH; Kuo, HC1

Reviews

1 review(s) available for doxazosin and celecoxib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for doxazosin and celecoxib

ArticleYear
Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    International journal of clinical practice, 2013, Volume: 67, Issue:12

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Biopsy; Celecoxib; Cyclooxygenase 2 Inhibitors; Doxazosin; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Pyrazoles; Sulfonamides; Treatment Outcome; Urination

2013

Other Studies

4 other study(ies) available for doxazosin and celecoxib

ArticleYear
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
    Journal of medicinal chemistry, 2013, Nov-14, Volume: 56, Issue:21

    Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Animals; CHO Cells; Cricetulus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Molecular Conformation; Molecular Targeted Therapy; Peptidyl-Dipeptidase A; Receptors, Dopamine D1; Receptors, Dopamine D2; Structure-Activity Relationship; Substrate Specificity

2013
Stability-indicating methods for the determination of doxazosin mezylate and celecoxib.
    Journal of pharmaceutical and biomedical analysis, 2002, Feb-01, Volume: 27, Issue:5

    Topics: Adrenergic alpha-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Densitometry; Doxazosin; Drug Stability; Pyrazoles; Spectrophotometry; Sulfonamides

2002